The clinical diagnosis of FHHNC needs to be confirmed by the detection of CLDN16 or CLDN19 pathogenic variants in both alleles. This evidence concerns the gene CLDN16 and familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis.